Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy. | |
Scambia, Giovanni; Johnson, Toby; Floquet, Anne; Heitz, Florian; Park, Sang-Yoon; Buck, Martin; Gallego, Rafael A. F. Alvarez; Shimada, Muneaki; Vergote, Ignace; Avall-Lundqvist, Elisabeth | |
2014 | |
卷号 | 32期号:15 |
ISSN号 | 0732-183X |
URL标识 | 查看原文 |
收录类别 | SCIE |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6667342 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Scambia, Giovanni,Johnson, Toby,Floquet, Anne,et al. Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy.[J],2014,32(15). |
APA | Scambia, Giovanni.,Johnson, Toby.,Floquet, Anne.,Heitz, Florian.,Park, Sang-Yoon.,...&Du Bois, Andreas.(2014).Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy..,32(15). |
MLA | Scambia, Giovanni,et al."Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy.".32.15(2014). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论